Asciminib: High Responses in Second-Line Chronic-Phase CML
Asciminib, a first-in-class BCR - ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line therapy for patients with chronic-phase chronic myeloid leukemia (CML) who had suboptimal responses to earlier therapies.
METHODOLOGY:
The interim analysis on the single-arm, open-label study, conducted at 85 trial sites in the US, included 101 patients with chronic-phase CML who discontinued a prior TKI due to intolerance or suboptimal responses.
Patients were treated with at least one dose of asciminib 80 mg once daily.
If BCR - ABL levels were above 1% at week 24, the dose was increased to 200 mg daily, and if BCR - ABL levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study.
- levels were above 1% at week 24, the dose was increased to 200 mg daily, and if - levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. Those with any grade 3 or 4 or persistent grade 2 toxicities that were refractory to optimal management were ineligible for dose escalations.
Reasons for prior treatment discontinuation were due to a lack of efficacy in 56.4% and intolerance in 43.6% of patients.
TAKEAWAY:
At week 24, a major molecular response was achieved by 44.4% of patients, with 25.4% achieving a deep molecular response (MR4 or better).
In all, 11.1% of patients were given dose escalations upon failing to achieve response milestones.
Among 101 patients receiving at least one dose, asciminib was well tolerated by most patients.
Asciminib's safety profile was that observed in previous studies, with no new or worsening safety findings observed.
Grade 3 and higher adverse events (AEs) included hypertension (8.9 %), thrombocytopenia (6.9%), and neutropenia (5.9%).
AEs overall led to dose adjustment or interruption in 26.7% of patients and discontinuation in four patients.
IN PRACTICE:
'Asciminib, in contrast with other FDA-approved TKIs, binds to the ABL myristoyl pocket, which may reduce off-target effects compared to the other competitive TKI's,' said first author David Jacob Andorsky, MD, of the Rocky Mountain Cancer Centers, US Oncology Research, Boulder, Colorado.
'Results from ASC2ESCALATE, the first prospective trial of asciminib in second-line chronic-phase CML with dose escalation in patients not achieving response milestones, further support asciminib as a treatment option in second-line chronic-phase CML,' he said.
'The outcomes in patients with asciminib dose escalations continue to be explored, with analyses planned for future presentations,' Andorsky noted.
SOURCE:
The analysis was presented at the American Society of Clinical Oncology (ASCO) 2025 in Chicago.
DISCLOSURES:
This study was sponsored by Novartis Pharmaceuticals. Andorsky reported having relationships with AbbVie, AstraZeneca, Celgene, and Novartis.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Grim underwater find prompts calls to make $43.9 million change in Aussie waters
Sea urchins are being found in alarming numbers in waters surrounding one of Australia's largest cities, but researchers believe culling them could create $92 million in benefits. A team from RMIT believe multiple industries could benefit if Port Phillip Bay's kelp forests they're destroying, are allowed to recover. Sea urchins are native to waters around Melbourne and feed on kelp, but warming waters and changing ocean currents have caused their numbers to reach 'unsustainable population levels', and pictures taken by RMIT divers show things are looking grim in many parts of the ocean. Kelp coverage in the greater region has declined by up to 98 per cent in the region over the last 40 years. Because the changing ocean conditions that favour the urchins are caused by climate change, their numbers aren't expected to naturally correct themselves, which is why the researchers argue intervention is needed. The study found that reducing urchin numbers and allowing the kelp forests to recover would reduce nitrogen and phosphorus in the water. Carrying out the plan would be expensive, with an investment of $43.9 million needed to create $92.1 million in benefits. But the study's lead author, Dr Paul Carnell, argues the plan would be a 'smart economic investment' for government. 'This approach can be targeted to specific areas of the bay, so we can get the greatest bang for our buck,' he said. 🪨 Inventor's valuable secret hidden beneath pile of rocks in outback 📸 Rare colour footage of extinct Australian animal seen again after 90 years 📍 Huge change to multi-million dollar block of land in busy suburb The plan could see the tourism sector profit as kelp forests are a drawcard for divers and snorkellers. Fish stocks would also likely improve, aiding both commercial and recreational fishers. But the biggest beneficiary would likely be the wider environment, as kept forests play an important role in water purification and carbon sequestering, a major cause of global warming. In Victoria, the collection of urchins is regulated, and there is a bag limit of 40. While they're in problematic numbers, they are actually a valuable resource and considered a delicacy in some Asian cultures. In Australia, some premium urchin roe can retail for almost $700 for 120 grams, but there are cheaper alternatives for as little as $60 per 100 grams. The study has been published in the journal published in Ecosystem Services. Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
WebMD
an hour ago
- WebMD
Living with Bipolar Disorder as a High-Achieving Woman
When Bipolar Disorder Meets Ambition Living with bipolar disorder isn't just about mood swings: It's about carrying an invisible weight that few people understand. For high-achieving women like me, that weight becomes even heavier. We're expected to hold everything together – family, career, responsibilities – while quietly battling chaos inside our own minds. The burnout that comes with bipolar disorder doesn't announce itself. It creeps in. One day you're pushing through your to-do list, the next you can't move from bed. It's not just exhaustion, it's emotional overload. The Mental Load No One Sees Living with bipolar disorder often feels like swimming in circles in the dark. You crave peace, but when a sliver of light finally appears, you don't trust it. You brace for the next crash. The fear of the unknown becomes just as heavy as the depression itself. When the depressive episodes hit, so do the thoughts: Why am I not like her? What's wrong with me? Did I cause this? I remember wondering if I was being punished for running away from home, for becoming a teen mom, for talking back, for leaving in the middle of the night. Burnout at Every Stage of Life The emotional burnout was always present, but it peaked during life transitions: When I became a teen mom When I went back to school After every child I had When I lost my husband When I tried dating again Each season added more weight. I was living life on edge, constantly trying to avoid pain. But when it finally hit, it hit hard. And it kept me stuck. Postpartum Depression and Family Silence I didn't recognize postpartum depression at first. I just knew I couldn't enjoy my babies the way I wanted to. I felt detached, overwhelmed, and guilty. Years later, I realized my mom had likely experienced the same thing. It opened my eyes to how generational silence keeps us sick. No one in my family knew I was struggling. They saw me tired, maybe reactive, but not in pain. I kept it inside. That silence cost me my peace. What I Missed While I Was Surviving Looking back, I see how much I missed: Real joy in motherhood Emotional connection in relationships Moments of financial peace True rest and presence Smiles that weren't just a mask The True Cost of Emotional Burnout Bipolar disorder is unpredictable. The highs and lows create stress and anxiety about the future. You lose your most valuable resources: time, energy, clarity, even money. And when you're stuck in that cycle, you miss the life happening right in front of you. I didn't know how to feel peace. I didn't know how to be present. I didn't know how to listen to my own voice, my intuition, my feelings. But I do now, and I support other women by helping them master their emotions, overcome burnout, and finally feel the peace and progress they've been chasing.
Forbes
an hour ago
- Forbes
First Pill For Obstructive Sleep Apnea Shows Promise In Phase 3 Study
The American Academy of Sleep Medicine has indicated that an estimated 26 percent of adults between ... More the ages of 30 and 70 years have sleep apnea. (Photo: Getty) You could say that it's difficult to mask the challenges that people with obstructive sleep apnea face every day. But if this pill from Apnimed, Inc. eventually gets approved by the U.S. Food and Drug Administration, it could give those OSA sufferers who are having trouble wearing a continuous positive airway pressure mask while sleeping another option. Apnimed recently announced rather eye-opening topline results from the SynAIRgy phase 3 clinical trial of their AD109 pill. A little over half (51.2%) of the study participants who took the once-a-day pill had a reduction in their OSA severity while nearly a quarter (22.3%) experienced achieved complete OSA control. Obstructive Sleep Apnea Affects A Quarter Of The Adult Population More options would probably be a welcome possibility for the over 25 million adults in the U.S. who suffer from OSA, based on the National Healthy Sleep Awareness Project. The American Academy of Sleep Medicine has indicated that an estimated 26 percent of adults between the ages of 30 and 70 years have sleep apnea. That may be an underestimate because people are kind of asleep when they are experiencing signs and symptoms of OSA. It could take someone else trying to share a bed with you to tell you that you are snoring or even gasping for breath when you are asleep. OSA is one type of sleep apnea. Sleep apnea is when you repeatedly stop and start breathing while sleeping. Its important to know if this is happening because breathing is sort of important. Sleep apnea can lead to sleep deprivation, which, in turn, can lead to daytime drowsiness and over the longer term various chronic medical conditions, as I've described previously in Forbes. One such condition is high blood pressure, which in turn can raise the risk of heart disease and stroke. OSA is when the apnea is due to your throat muscles relaxing too much and blocking your airway. That's why one possible sign of OSA is snoring, which can occur when air tries to pass through the narrowed airway. The following illustration shows what can happen to the airway with OSA: (Illustration: Getty) Here Are The Current Treatment Options For Obstructive Sleep Apnea All of the currently available treatment options for OSA are focused on one thing: keep that airway open as much as possible. Changes in sleep position could help. For example, sleeping on your side, particularly the left side, can keep the airway open better than sleeping on your back. the latter can allow your tongue and soft palate to collapse into your airway. One oft-mentioned treatment option is the CPAP mask. The name is a clue to what it does. You wear a mask that will continuously will blow air into your nose or nose and mouth. That air is supposed to provide positive pressure to keep your airways open, sort of like blowing air into one of those balloons that can become a balloon animal. Although a variety of such masks are available, wearing such a mask throughout the night may not necessarily be the most pleasant, comfortable or sexy thing. Another option is some kind of mouthpiece designed to keep the throat open during sleep. Some such devices thrust your lower jaw forward. Other such devices hold your tongue is particular positions. When OSA gets particularly severe, surgery may be needed. This could be surgery to remove excess tissue in the neck that may be blocking the airway or move forward the jaw bones to give more space behind the tongue and soft palate. Life-threatening cases of OSA may even require a tracheostomy, which is when a hole is made in your throat and a breathing tube is inserted there. Now you may have heard about one of the glucagon-like peptide-1 receptor agonists, Zepbound, getting FDA-approval for severe OSA. This would be mainly for folks who have OSA due mainly to obesity. Excess fatty tissue in the neck can indeed predispose you to OSA. Therefore, weight loss can be helpful in reducing OSA. However, many people suffer from OSA do not have excess body weight. For many, it's just the anatomy of the airway and the way the nerves happen to be working or not working that allows too much collapse of the airway. The Apnimed Pill Could Become The First Prescription Pull For Obstructive Sleep Apnea This brings us to how AD109 is supposed to work. The medication is a combo of 2.5 mg of aroxybutynin, a new type of antimuscarinic, and 75 mg atomoxetine, which inhibits the reuptake of the neurotransmitter norepinephrine, thereby increasing the time it spends in between nerves. These work to increase the nerve signals sent through the hypoglossal motor nucleus that control the muscles in the upper airway. The medication has already gone through more than 15 Phase 1 and 2 clinical trials. A Phase 2b clinical trial named MARIPOSA showed that those taking AD109 experienced statistically significant reductions in their AHIs. AHI stands for apnea-hypopnea index, a commonly used measure of how severe sleep apnea is. The AHI is the average number of apneas, which are complete pauses in breathing, and hypopneas, which are partial reductions in breathing, that happen per hour of sleep during a sleep study. Normally, this should be less than five. Having five to 14 such events per hour classifies you as having mild sleep apnea. When this goes up to 15 to 29, it's moderate sleep apnea. The severe range is 30 or more such events per hour. Next up was the SynAIRgy trial, a randomized, double blind, placebo-controlled, parallel-arm of the medication designed to extend for six months. It included 646 adult study participants with OSA who either couldn't tolerate or didn't want to use CPAP. Around half (49.1%) of the study participants were women. At the beginning of the trial, 34.4% had mild OSA, 42.2% moderate and 23.2% severe. Patrick Strollo, Jr., MD, Vice Chair of Medicine for Veteran's Affairs and a Professor of Medicine at the University of Pittsburgh School of Medicine. served as the study chair of SynAIRgy. Strollo described the results so far as 'highly encouraging." At the 26-week mark in the SynAIRgy trial, those taking AD109 every day had on average a 55.6% reduction in their AHI. As mentioned previously, 51.2% actually dropped in sleep apnea disease severity categories with 22.3% going to the no apnea category, namely less than five events per hour. Those taking AD109 also on average had improvements in the amount of oxygen they were getting into their blood via their lungs. There were also no AD109-related serious adverse events with the medication in general being well-tolerated. Topline results from a second Phase 3 clinical trial, LunAIRo, will probably be available by the third quarter of 2025. All of this means that the company is currently on track to submit a New Drug Application for AD109 to the FDA by early 2026. If it reaches the market, AD109 would be the first prescription pill specifically for obstructive sleep apnea—which, again, affects quite a lot of people out there, probably much more than people realize. So don't sleep on what happens next.
